MetLife (NYSE:MET – Free Report) had its target price lifted by UBS Group from $94.00 to $98.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the financial services provider’s stock.
Several other equities research analysts also recently issued reports on the stock. Keefe, Bruyette & Woods cut their target price on shares of MetLife from $100.00 to $98.00 and set an “outperform” rating for the company in a research note on Wednesday, February 12th. Wells Fargo & Company raised their price objective on MetLife from $92.00 to $97.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Piper Sandler increased their price target on MetLife from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday. Barclays cut their price target on MetLife from $96.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, February 7th. Finally, StockNews.com lowered shares of MetLife from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $94.85.
MetLife Trading Down 9.5 %
MetLife (NYSE:MET – Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The financial services provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.13 by ($0.05). MetLife had a return on equity of 20.42% and a net margin of 6.19%. Equities research analysts predict that MetLife will post 9.65 earnings per share for the current fiscal year.
MetLife Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 11th. Investors of record on Tuesday, February 4th were given a dividend of $0.545 per share. This represents a $2.18 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date was Tuesday, February 4th. MetLife’s dividend payout ratio is currently 36.52%.
Institutional Trading of MetLife
Several large investors have recently modified their holdings of MET. CX Institutional lifted its position in MetLife by 15.9% during the fourth quarter. CX Institutional now owns 68,005 shares of the financial services provider’s stock worth $5,568,000 after purchasing an additional 9,337 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of MetLife by 109.2% during the 4th quarter. Bank of New York Mellon Corp now owns 8,826,658 shares of the financial services provider’s stock worth $722,727,000 after acquiring an additional 4,606,748 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of MetLife by 27.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 13,692 shares of the financial services provider’s stock worth $1,116,000 after acquiring an additional 2,940 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in MetLife by 1.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 776,244 shares of the financial services provider’s stock valued at $63,559,000 after acquiring an additional 12,723 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC acquired a new position in MetLife during the fourth quarter valued at approximately $259,000. 94.99% of the stock is owned by institutional investors and hedge funds.
MetLife Company Profile
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Recommended Stories
- Five stocks we like better than MetLife
- How Technical Indicators Can Help You Find Oversold Stocks
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.